NOVO — Januar 2025
-
I tirsdagens formarked indikeres Eli Lilly-aktien 0,1 pct. lavere i 796,84 dollar Marketwire
-
USA/åbning: Eli Lilly dykker efter svag afslutning på 2024 i grønt marked https://proinvestor.com/investornyt/1265138/usa-abning-eli-lilly-dykker-efter-svag-afslutning-pa-2024-i-gront-marked
-
JPM Spår fint regnskab https://www.sydinvest.dk/nyheder/novo-nordiskjpm-spaar-fint-regnskab-og-solid-prognose-fo
-
Er det "fair" at svage LLY tal får Novo Nordisk til at falde https://proinvestor.com/boards/124155
-
Lilly's overoptimistic view on obesity market leads to revenue miss in 2024 https://firstwordpharma.com/story/5927673
-
Novo-rival ramt af overraskende udvikling i december https://proinvestor.com/investornyt/1265446/novo-rival-ramt-af-overraskende-udvikling-i-december
-
Novo Nordisk og CagriSema-skuffelsen https://proinvestor.com/investornyt/1265521/novo-nordisk-og-cagrisema-skuffelsen
-
Investeringspodcasten: Fortsætter de danske aktier som Novo, Mærsk, Vestas og Ørsted ned? Og stiger renten? Hør om dette og meget mere i afsnit 257 af Investeringspodcasten. https://proinvestor.com/boards/124182
-
Ny joker på spil i Novos guldrandede fedmetogt https://finans.dk/erhverv/ECE17805254/ny-joker-paa-spil-i-novos-guldrandede-fedmetogt/?utm_campaign=FINANS Briefing&utm_content=2025-01-16&utm_medium=email&utm_source=finans
-
Novo-rival får gentaget købsanbefaling før studie af fedmepille https://proinvestor.com/investornyt/1265937/novo-rival-far-gentaget-kobsanbefaling-for-studie-af-fedmepille
-
Kort videokommentar: Novo, Eli Lilly, Zealand Pharma, Gubra, Genmab, Anavex: https://proinvestor.com/boards/124218
-
Analytikere er langt mere positive, end de plejer. 32 danske aktier spås kursstigninger på over 10 pct. i 2025. +42,1% i Novo https://borsen.dk/nyheder/investor/analytikere-sa-meget-skal-danske-aktier-stige?b_source=borsen&b_medium=row_0&b_campaign=news_1
-
Fra Reuters "Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus
By Patrick Wingrove
Jan 16 (Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk, hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the investment firm said, as it prepares for a likely focus on U.S. manufacturing by President-elect Donald Trump.
Novo Holdings last month closed a $16.5 billion deal to buy U.S.-based -
Catalent. The firm then sold three of Catalent's plants used to complete the drug manufacturing process to Novo Nordisk for $11 billion as part of the deal, to help the Danish drugmaker ramp up supplies of its popular weight-loss drug Wegovy.
Jonathan Levy, the Novo Holdings partner who led the deal, in an interview this week said his firm did not want to overcommit to a revenue target before it had a chance to set out a corporate strategy with Catalent's management.
"But doubling the size of -
your business over five years is always a nice barometer to work on, and I think we could do something more here from an enterprise value perspective," Levy told Reuters at the JPMorgan health conference in San Francisco.
Catalent, which had sales of $4.38 billion in 2024, will hold its next board meeting in February, according to Levy.
Levy said he expects more drugmakers that currently rely on manufacturers in China and India to look for western service providers with Trump set to return to -
to the White House on Monday, given his America first focus.
Catalent and Thermo Fisher Scientific unit Patheon -- two of the largest contract drug manufacturers based in the U.S. -- could be beneficiaries of such moves.
In addition to his outspoken preference for U.S. manufacturing, Trump has said he will hit China with new tariffs on the first day of his presidency, but Levy did not discuss how that might affect pharmaceuticals.
Levy said Novo Holdings has a venture vehicle with more than 90 -
biopharmaceutical assets that will be "a tremendous pipeline" for Catalent.
He also said he was closely watching lawmaker efforts to pass a bill that would restrict U.S. business with certain Chinese biotechnology companies, including contract drug manufacturer WuXi AppTec.
"Companies like WuXi, for example, they (will) struggle as a result of it," Levy said, "and companies like Catalent will benefit."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind